dc.contributor.author
Adams, Lisa C.
dc.contributor.author
Lübbe, Falk
dc.contributor.author
Bressem, Keno
dc.contributor.author
Wagner, Moritz
dc.contributor.author
Hamm, Bernd
dc.contributor.author
Makowski, Marcus R.
dc.date.accessioned
2019-04-01T15:22:36Z
dc.date.available
2019-04-01T15:22:36Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/24256
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-2028
dc.description.abstract
Non-alcoholic fatty liver disease (NAFLD) was shown to also occur in lean and underweight patients. So far, the prevalence of NAFLD in underweight individuals with and without inflammatory bowel disease (IBD) is insufficiently enlightened. In this cross-sectional age, gender and disease-matched case-control study, underweight patients (BMI<18.5 kg/m(2)) with inflammatory bowel disease (IBD), who underwent abdominal MRI at 1.5 T/3 T with fat-saturated fast-spin-echo imaging from 10/2005-07/2018 were analysed (control-to-caseratio 1:1, n = 130). All patients were additionally investigated for duration, history of surgery, medical treatment, laboratory values, liver and spleen diameters. On MRI, liver fat was quantified by two observers based on the relative signal loss on T2-weighted fast spin-echo MR images with fat saturation compared to images without fat saturation. The prevalence of NAFLD/liver steatosis, defined as a measured intrahepatic fat content of at least 5%, was significantly higher in underweight IBD patients than in normal weight patients (87.6% versus 21.5%, p<0.001). Compared to the cases, the liver fat content of the controls was reduced by -0.19 units on average (-19%; 95%CI: -0.20; -0.14). Similar results were obtained for the subgroup of non-IBD individuals (n = 12; -0.25 units on average (-25%); 95%CI: -0.35; -0.14). Patients with extremely low body weight (BMI <17.5 kg/m(2)) showed the highest liver fat content (+0.15 units on average (+15%) compared to underweight patients with a BMI of 17.5-18.5 kg/m(2) (p<0.05)). Furthermore, underweight patients showed slightly increased liver enzymes and liver diameters. There were no indications of significant differences in disease duration, type of medications or surgery between cases and controls and also, there were no significant differences between observers or field strengths (p>0.05). The prevalence of liver steatosis was higher among underweight IBD and non-IBD patients compared to normal weight controls. Also, underweight patients showed slightly increased liver enzymes and liver diameters, hinting at initial metabolic disturbances.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Non-alcoholic fatty liver disease (NAFLD)
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: A case-control study
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
e0206450
dcterms.bibliographicCitation.doi
10.1371/journal.pone.0206450
dcterms.bibliographicCitation.journaltitle
PLoS ONE
dcterms.bibliographicCitation.number
11
dcterms.bibliographicCitation.originalpublishername
Public Library of Science (PLoS)
dcterms.bibliographicCitation.volume
13
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
30427909
dcterms.isPartOf.issn
1932-6203